Zobrazeno 1 - 10
of 829
pro vyhledávání: '"David R, Gandara"'
Autor:
Jonathan W. Riess, MD, Matthew S. Lara, BS, Miguel Lopez de Rodas, MD, Guillaume Luxardi, PhD, Samantha Herbert, MSPH, Michiko Shimoda, PhD, Karen Kelly, MD, Alexander Meerlev, PhD, Elizabeth Moore, MD, Laurel Beckett, PhD, Arta Monjazeb, MD, PhD, Kurt Schalper, MD, PhD, Emanual Maverakis, MD, David R. Gandara, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 10, Pp 100706- (2024)
Introduction: EGFR-mutated NSCLC is minimally responsive to programmed cell death protein 1 or programmed death-ligand 1 blockade. We evaluated the safety, tolerability, and immunomodulatory effects of the EGFR tyrosine kinase inhibitor (TKI) afatini
Externí odkaz:
https://doaj.org/article/863cfd19d5dc48c7a90762bd86354f28
Autor:
Harsha Ranganath, Amit L. Jain, Justin R. Smith, Julie Ryder, Amina Chaudry, Emily Miller, Felicia Hare, Poojitha Valasareddy, Robert S. Seitz, David R. Hout, Matthew G. Varga, Brock L. Schweitzer, Tyler J. Nielsen, Janice Mullins, Douglas T. Ross, David R. Gandara, Gregory A. Vidal
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background Immune checkpoint inhibitor (ICI) therapies represent a major advance in treating a variety of advanced-stage malignancies. Nevertheless, only a subset of patients benefit, even when selected based on approved biomarkers such as P
Externí odkaz:
https://doaj.org/article/ca410bdf72ce41f5b615b14aab591ed1
Autor:
Matthew S. Lara, BS, Matthew A. Gubens, MD, Bianca Bacaltos, MS, Lea Daran, BA, Steffany L. Lim, BS, Tianhong Li, MD, David R. Gandara, MD, Trever G. Bivona, MD, PhD, Jonathan W. Riess, MD, Collin M. Blakely, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 12, Pp 100436- (2022)
Introduction: In patients with NSCLC harboring oncogenic ALK or ROS1 rearrangements, tyrosine kinase inhibitors have yielded high response rates and improvements in progression-free survival compared with cytotoxic chemotherapy; however, acquired res
Externí odkaz:
https://doaj.org/article/bdec48648e1f4cfea18683ee2ea77829
Autor:
Christian Caglevic, Christian Rolfo, Ignacio Gil-Bazo, Andrés Cardona, Jorge Sapunar, Fred R. Hirsch, David R. Gandara, Gilberto Morgan, Silvia Novello, Marina-Chiara Garassino, Giannis Mountzios, Natasha B. Leighl, Denisse Bretel, Oscar Arrieta, Alfredo Addeo, Stephen V. Liu, Luis Corrales, Vivek Subbiah, Francisco Aboitiz, Franz Villarroel-Espindola, Felipe Reyes-Cosmelli, Ricardo Morales, Mauricio Mahave, Luis Raez, Jorge Alatorre, Edgardo Santos, Luis Ubillos, Daniel S.W. Tan, Christoph Zielinski
Publikováno v:
JCO Global Oncology, Vol , Iss 8 (2022)
On February 24, 2022, a war began within the Ukrainian borders. At least 3.0 million Ukrainian inhabitants have already fled the country. Critical infrastructure, including hospitals, has been damaged. Children with cancer were urgently transported t
Externí odkaz:
https://doaj.org/article/169c0613581d4a2aac6760d22c60d06f
Autor:
Roy S Herbst, Naiyer Rizvi, Karen Kelly, Vassiliki A Papadimitrakopoulou, Natasha B Leighl, Mary W Redman, Fred R Hirsch, Philip C Mack, Lawrence H Schwartz, James L Wade, William J Irvin, Sreekanth C Reddy, Jeffrey Crawford, Jeffrey D Bradley, Thomas E Stinchcombe, Suresh S Ramalingam, Jieling Miao, Katherine Minichiello, David R Gandara
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Externí odkaz:
https://doaj.org/article/aa42cd2cdcbe45b39c93537b9fab9f89
Autor:
Lorinda Simms, Shehkar Patil, David R. Gandara, Anders Mellemgaard, Raghunadharao Digumarti, Bonne Biesma, Johan Vansteenkiste, Mauro Zukin, Joachim von Pawel, Katherine P. Sugarman, Keunchil Park, Christian Manegold, Filippo de Marinis, Tuncay Göksel, Janusz Rolski, Piotr Serwatowski, Jin S. Lee, Giorgio V. Scagliotti, Ulrich Gatzemeier, Purvish M. Parikh
Publikováno v:
Journal of Clinical Oncology. 41:2458-2466
PURPOSE Cisplatin plus gemcitabine is a standard regimen for first-line treatment of advanced non–small-cell lung cancer (NSCLC). Phase II studies of pemetrexed plus platinum compounds have also shown activity in this setting. PATIENTS AND METHODS
Autor:
Amy Burd, Richard L. Schilsky, John C. Byrd, Ross L. Levine, Vassiliki A. Papadimitrakopoulou, Roy S. Herbst, Mary W. Redman, Brian J. Druker, David R. Gandara
Publikováno v:
Blood Advances, Vol 3, Iss 14, Pp 2237-2243 (2019)
Abstract: The appetite for cutting-edge cancer research, across medical institutions, scientific researchers, and health care providers, is increasing based on the promise of true breakthroughs and cures with new therapeutics available for investigat
Externí odkaz:
https://doaj.org/article/1cd08a7cb2754c7491bebd002f449233
Autor:
Joseph M Unger, Lu Qian, Mary W Redman, Susan S Tavernier, Lori Minasian, Ellen V Sigal, Vassiliki A Papadimitrakopoulou, Michael Leblanc, Charles S Cleeland, Samuel A Dzingle, Thomas J Summers, Herta Chao, Sheshadri Madhusudhana, Liza Villaruz, Jeffrey Crawford, Jhanelle E Gray, Karen L Kelly, David R Gandara, Lyudmila Bazhenova, Roy S Herbst, Scott N Gettinger, Carol M Moinpour
Publikováno v:
JNCI: Journal of the National Cancer Institute. 115:437-446
Background An important issue for patients with cancer treated with novel therapeutics is how they weigh the effects of treatment on survival and quality of life (QOL). We compared QOL in patients enrolled to SWOG S1400I, a substudy of the LungMAP bi
Autor:
Xing Yi Woo, Anuj Srivastava, Philip C. Mack, Joel H. Graber, Brian J. Sanderson, Michael W. Lloyd, Mandy Chen, Sergii Domanskyi, Regina Gandour-Edwards, Rebekah A. Tsai, James Keck, Mingshan Cheng, Margaret Bundy, Emily L. Jocoy, Jonathan W. Riess, William Holland, Stephen C. Grubb, James G. Peterson, Grace A. Stafford, Carolyn Paisie, Steven B. Neuhauser, R. Krishna Murthy Karuturi, Joshy George, Allen K. Simons, Margaret Chavaree, Clifford G. Tepper, Neal Goodwin, Susan D. Airhart, Primo N. Lara, Thomas H. Openshaw, Edison T. Liu, David R. Gandara, Carol J. Bult
Publikováno v:
Cancer Res
Cancer research, vol 82, iss 22
Cancer research, vol 82, iss 22
Patient-derived xenograft (PDX) models are an effective preclinical in vivo platform for testing the efficacy of novel drugs and drug combinations for cancer therapeutics. Here we describe a repository of 79 genomically and clinically annotated lung
Autor:
Shirish M. Gadgeel, Jieling Miao, Jonathan W. Riess, James Moon, Philip C. Mack, Gregory J. Gerstner, Timothy F. Burns, Asma Taj, Wallace L. Akerley, Konstantin H. Dragnev, Noel Laudi, Mary W. Redman, Jhanelle E. Gray, David R. Gandara, Karen Kelly
Publikováno v:
Clinical Cancer Research.
Purpose: Efficacy of MEK inhibitors in KRAS+ NSCLC may differ based on specific KRAS mutations and co-mutations. Our hypothesis was that docetaxel and trametinib would improve activity in KRAS+ NSCLC and specifically in KRAS G12C NSCLC. Patients and